Cardiovascular safety of Osimertinib in non-small cell lung cancer patients

被引：0
|
作者：
Chavan, Ashish [1 ]
Shirsat, Aditi [1 ]
Chopade, Sunil [1 ]
Menon, Nandini [1 ]
Patil, Vijay [1 ]
Noronha, Vanita [1 ]
Gota, Vikram [1 ]
Prabhash, Kumar [1 ]
Nookala, Manjunath [1 ]
机构：
[1] Tata Mem Hosp, Actrec, Parel, India
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P0858
引用
收藏
页码：161 / 162
页数：2
相关论文
共 50 条
  • [41] Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
    Chen, Lanyi Nora
    Ma, Xin
    Herzberg, Benjamin
    Henick, Brian S.
    Biswas, Anup K.
    Acharyya, Swarnali
    Shu, Catherine A.
    ONCOLOGIST, 2024,
  • [42] Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer
    Yokota, Hayato
    Sato, Kazuhiro
    Sakamoto, Sho
    Okuda, Yuji
    Takeda, Masahide
    Akamine, Yumiko
    Nakayama, Katsutoshi
    Miura, Masatomo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [43] Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
    van Veggel, B.
    van der Wekken, A.
    Hashemi, S.
    Cornelissen, R.
    Monkhorst, K.
    Heideman, D.
    Radonic, T.
    Smit, E. F.
    Schuuring, E.
    De Langen, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [45] EFFECTIVENESS AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH LEPTOMENINGEAL METASTASES FORM NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Wen, Lei
    Shan, Changguo
    Wang, Hui
    Yang, Yanying
    Ye, Minting
    Hong, Weiping
    Cai, Linbo
    NEURO-ONCOLOGY, 2021, 23 : 75 - 75
  • [46] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, S. A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ma, X.
    Ali, S.
    Miller, V. A.
    Popat, S.
    VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
  • [47] Osimertinib for non-small-cell Lung Cancer
    Alakus, Hakan
    Zander, Thomas
    Bruns, Christiane
    ONKOLOGE, 2018, 24 (02): : 174 - 176
  • [48] An innovative AXL blocker eliminates osimertinib resistance in non-small cell lung cancer
    Rhie, Byung-Ho
    Choi, Myeong Jun
    Park, Young Jun
    Kim, Sammy L.
    Hong, Yoonki
    Ramakrishna, Suresh
    CANCER SCIENCE, 2025, 116 : 337 - 337
  • [49] Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
    Liu, Shengwu
    Li, Shuai
    Hai, Josephine
    Wang, Xiaoen
    Chen, Ting
    Quinn, Max M.
    Gao, Peng
    Zhang, Yanxi
    Ji, Hongbin
    Cross, Darren A. E.
    Wong, Kwok-Kin
    CLINICAL CANCER RESEARCH, 2018, 24 (11) : 2594 - 2604
  • [50] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
12345